AveXis (AVXS) PT Raised to $79 at Jefferies

November 14, 2016 8:18 AM EST
Get Alerts AVXS Hot Sheet
Price: $55.64 -2.2%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade AVXS Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst Biren Amin reiterated a Buy rating and boosted his price target on AveXis (NASDAQ: AVXS) to $79.00 (from $71.00).

Amin commented, "The EMA hosted a workshop on Friday to discuss pot'l trial designs for SMA Type 1 which may influence AVXS' development plan in EU. We are more confident that EMA could follow FDA's steps and approve on a single arm design trial so long as a significant effect is achieved over baseline on a motor milestone such as sitting in the pivotal study. We therefore lower our ex-U.S risk discount which increases our PT to $79 (from $71)."

For an analyst ratings summary and ratings history on AveXis click here. For more ratings news on AveXis click here.

Shares of AveXis closed at $67.35 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

Jefferies & Co

Add Your Comment